Vir Biotechnology, Inc. (VIR) SEC Filings & Earnings Calls

Preclinical stage; no guarantee of successful development or commercialization.

“Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product.” · word for word

Clinical and regulatory risk remains; Fast Track does not guarantee approval.

“Fast Track designation is a regulatory milestone, not approval.”

Clinical trial risk: Phase 3 ECLIPSE data expected in Q4 2026 and Q1 2027; failure could impact pipeline value.

“Topline data from Phase 3 ECLIPSE 1 trial expected in the fourth quarter of 2026; ECLIPSE 2 and 3 in Q1 2027.” · word for word

Dependence on collaboration: Astellas partnership provides funding but also dependency on partner execution.

“Closed global strategic collaboration with Astellas; received $240M upfront and $75M equity investment.”

Clinical Development Risk

“Our future success is substantially dependent on the successful clinical development, regulatory approval and commercialization of our product candidates in a timely manner.” · word for word

Net Loss History

“We have incurred net losses and anticipate that we will continue to incur net losses in the foreseeable future.” · word for word

Management Transition Risk

“On July 20, 2026, Jason O’Byrne, MBA, our Executive Vice President and Chief Financial Officer, informed us that he would be stepping down from his role, effective August 3, 2026.” · word for word

CFO departure may signal internal challenges or distract from operations; search for successor introduces uncertainty.

“CFO stepping down effective Aug 3, 2026; search initiated for successor.”

Clinical Trial Failure Risk

“Topline data from the Phase 3 ECLIPSE 1 trial are expected in the fourth quarter of 2026. Topline data from the ECLIPSE 2 and ECLIPSE 3 trials are expected in the first quarter of 2027.” · word for word

Dependence on Key Personnel

“On April 7, 2026, Mark Eisner, MD, MPH, Executive Vice President and Chief Medical Officer...informed us that he will be stepping down from his role, effective April 24, 2026.” · word for word

Accumulated Deficit

“As of March 31, 2026, we had an accumulated deficit of $1.3 billion.” · word for word

Net loss continues; no approved products; reliance on pipeline success and partnerships.

“Net loss $125.7M; no revenue from products.”

Clinical trial risk: Phase 3 data expected late 2026/early 2027; regulatory approval uncertain.

“Topline data from Phase 3 ECLIPSE 1 expected Q4 2026; ECLIPSE 2/3 in Q1 2027.”

Pre-commercial stage with significant net losses

“Net Income ($ in thousands) $(437,987)”

CMO departure creates clinical development execution risk

“On April 7, 2026, Dr. Eisner informed us that he would step down from his role, effective April 24, 2026.” · word for word

Stock price volatility and low absolute level

“closing price of $6.03 per share of our common stock on December 31, 2025” · word for word

Loss of key R&D leadership could delay clinical trials or regulatory interactions.

“CMO departure with no named successor; search initiated.”

Dilution from equity offering; company may need further capital.

“20,294,117 shares issued; gross proceeds $172.5M.”

Clinical and regulatory risks remain for pipeline programs.

“Drug development involves high risk; only small number of programs result in commercialization.”

Continued net losses and need for additional funding

“We have incurred net losses and anticipate that we will continue to incur net losses in the foreseeable future. ... We had net loss of $438.0 million and $522.0 million for the years ended December 31, 2025, and 2024, respectively. As of December 31, 2025, we had an accumulated deficit of $1.2 billion.” · word for word

Clinical development and regulatory approval risk

“Our future success is substantially dependent on the successful clinical development, regulatory approval and commercialization of our product candidates in a timely manner. If we are not able to obtain required regulatory approvals, we will not be able to commercialize our product candidates, and our ability to generate product revenue will be adversely aff” · word for word

Dependence on third-party manufacturers and suppliers

“We rely on third parties to produce clinical and future commercial supplies of our product candidates. There could be delays or supply shortages beyond our control limiting our access to clinical and future commercial supplies.” · word for word

Drug pricing and reimbursement pressure from IRA

“The IRA: requires manufacturers of certain drugs to engage in price negotiations with Medicare (to go into effect in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the prior Part D coverage gap discount p” · word for word

Dependence on key personnel and ability to manage growth

“We are highly dependent on our key personnel, and if we are not able to retain these members of our management team or recruit and retain additional management, clinical and scientific personnel, our business could be harmed.” · word for word

Clinical trial risks: Phase 3 ECLIPSE data not expected until late 2026/early 2027; pipeline dependency on single platform.

“Topline data from the ECLIPSE 1 trial is expected in the fourth quarter of 2026. Topline data from the ECLIPSE 2 and ECLIPSE 3 trials are expected in the first quarter of 2027.” · word for word

No revenue or earnings guidance provided; company is pre-revenue.

“No financial results or guidance provided beyond cash position.”

Regulatory approval required for certain jurisdictions; clinical trial risk remains.

“closing ... subject to Norgine receiving regulatory approval from applicable authorities”

No approved products; reliance on clinical-stage pipeline

“Other than sotrovimab, we have not obtained regulatory approval for our product candidates, and we do not expect to generate any significant revenue from the sale of our product candidates until we complete clinical development.” · word for word

Significant operating losses and accumulated deficit

“We have incurred net losses and anticipate that we will continue to incur net losses in the foreseeable future.” · word for word

Dependence on collaboration agreements

“We are a party to strategic collaboration and license agreements pursuant to which we are obligated to make substantial payments upon achievement of milestone events.” · word for word

Revenues are minimal ($0.2M) and declining; company is pre-revenue and relies on cash reserves.

“Total revenues $0.2M vs $2.4M prior year.”

Clinical and regulatory risk: pipeline programs are still in Phase 1-3; no approved products; data readouts are years away.

“ECLIPSE topline data expected Q1 2027; VIR-5500 data update Q1 2026; all programs are investigational.”